Sukhi Thethy
Comptroller/Controller/Auditor chez CHINOOK THERAPEUTICS, INC.
Postes actifs de Sukhi Thethy
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| CHINOOK THERAPEUTICS, INC. | Comptroller/Controller/Auditor | - | - |
Historique de carrière de Sukhi Thethy
Anciens postes connus de Sukhi Thethy
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| AIMMUNE THERAPEUTICS, INC. | Comptroller/Controller/Auditor | - | - |
Formation de Sukhi Thethy
| San Jose State University | Graduate Degree |
Statistiques
Internationale
| Etats-Unis | 4 |
Opérationnelle
| Comptroller/Controller/Auditor | 2 |
| Graduate Degree | 1 |
Sectorielle
| Health Technology | 3 |
| Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Chinook Therapeutics, Inc.
 Chinook Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. The company was founded in 2019 and is headquartered in Seattle, WA. | Health Technology |
Aimmune Therapeutics, Inc.
 Aimmune Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The firm product include Palforzia, which is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis that may occur with accidental exposure to peanut. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA. | Health Technology |
- Bourse
- Insiders
- Sukhi Thethy
- Expérience
